Adjuvant therapy for pancreatic adenocarcinoma.
Abrams
R A
RA
Division of Radiation Oncology, Johns Hopkins Oncology Center, 600 N. Wolfe St., Baltimore, MD 21287, USA.
D000230:Adenocarcinoma / Q000401:mortality / Q000628:therapy*; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D017322:Clinical Trials, Phase II as Topic; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008113:Liver Neoplasms / Q000532:radiotherapy / Q000556:secondary; D016685:Mitomycin / Q000008:administration & dosage; D010190:Pancreatic Neoplasms / Q000401:mortality / Q000628:therapy*; D016577:Pancreaticoduodenectomy; D018714:Radiotherapy, Adjuvant; D012107:Research Design; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome
D000903:Antibiotics, Antineoplastic; D000964:Antimetabolites, Antineoplastic; D016685:Mitomycin; D005472:Fluorouracil